Drug name - Chantix
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(4 months ago) | |
| US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(2 months ago) | |
| CN100370987C | PF PRISM CV | 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0. 2.11. 0. 4.9]--2 (11), 3, 5, 7, 9, - Pentaene-Tartrate |
Apr, 2022
(5 months ago) | |
| CN1509174A | PF PRISM CV | 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0 |
Apr, 2022
(5 months ago) | |
| IN204091B | PF PRISM CV | Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| IN200300863P3 | PF PRISM CV | Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| EP1392307A1 | PF PRISM CV | Tartrate Salts Of 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| EP1392307B1 | PF PRISM CV | Tartrate Salts Of 5,8,14-Triazatetracyclo¬10.3.1.02,11.04,9-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6890927
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(a month from now) | |
|
US7265119
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(3 months from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.5MG BASE | TABLET;ORAL | Prescription |
| EQ 1MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.